{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019285","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.903413+00:00","generated_at":"2026-06-25T21:48:38.664750+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AbCellera Q1 2022 revenue $317M, net earnings $0.59/sh, up from $0.43/sh YoY","bullets":["Total revenue $316.6M (up 56% YoY from $202.7M); net earnings $168.6M ($0.59 basic EPS vs $0.43).","Royalties from bamlanivimab/bebtelovimab contributed $307M of total revenue.","Cumulative program starts reached 84 (up 56% YoY); discovery partners grew to 36 from 29.","Cash, cash equivalents and marketable securities stood at $786.1M.","R&D expenses rose to $26.4M from $12.4M YoY, driven by platform investment."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019285","json":"https://secwatch.observer/filing/0001564590-22-019285.json","markdown":"https://secwatch.observer/filing/0001564590-22-019285.md","text":"https://secwatch.observer/filing/0001564590-22-019285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022019285/0001564590-22-019285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022019285/abcl-8k_20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:48:38.664750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}